FIGURE 2.

Event rate with benralizumab versus placebo for the composite end-point for exacerbations (CompEx), severe exacerbations (SevEx) and acute worsening events (AWEs) for patients aged ≥16 years by baseline blood eosinophil count category (0–150 cells·µL⁻¹, 150–300 cells·µL⁻¹, 300–450 cells·µL⁻¹ and >450 cells·µL⁻¹) for SIROCCO and CALIMA studies (pooled data). A restricted model was used with only treatment and study as factors.